250,000-share insider purchase signals confidence at Vera Therapeutics
Rhea-AI Filing Summary
Vera Therapeutics (VERA) filed a Form 4 showing director Patrick G. Enright, through Longitude Prime Fund and Longitude Venture Partners IV, bought 250,000 Class A shares on 23–24 Jun 2025 at weighted-average prices of $20.87–$22.35, spending roughly $5.3 million. Post-transaction indirect holdings rise to 5,394,212 shares, an increase of about 4.9%. All trades were open-market purchases (code 'P'); no sales or derivatives were reported. Footnotes disclose price ranges and standard Section 16 disclaimers. The scale and direction of the trade suggest insider confidence, but the filing offers no strategic commentary.
Positive
- $5.3 million insider purchase (250,000 shares) at ~$21.11 average, materially increasing indirect holdings to 5.39 million shares
Negative
- None.
Insights
TL;DR: $5.3 M fund-level insider buy, no sales—bullish signal on valuation and outlook.
The coordinated purchase of 250,000 shares across two Longitude funds adds roughly 4.9% to their position, lifting indirect ownership to 5.39 million shares. Dollar value surpasses $5 million, well above routine thresholds and implying high conviction near recent price highs. Absence of 10b5-1 plan or derivative hedges points to discretionary buying. Such scale from a board member often precedes positive catalysts and tightens float, potentially supporting near-term share performance. Investors should, however, monitor future filings for additional accumulation or any switch to distribution mode.
TL;DR: Positive sentiment, but indirect fund ownership tempers alignment; exit risk remains.
Although sizeable, the purchase was executed through venture funds, not personal accounts, limiting direct governance alignment and introducing eventual liquidity overhang when funds exit. Weighted-average prices indicate opportunistic accumulation rather than urgency, implying moderate—not emphatic—bullishness. Without complementary operational news, the transaction alone is unlikely to reshape long-term fundamentals, but it does modestly improve near-term sentiment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Class A Common Stock | 13,536 | $22.3517 | $303K |
| Purchase | Class A Common Stock | 27,071 | $22.3517 | $605K |
| Purchase | Class A Common Stock | 69,798 | $20.8683 | $1.46M |
| Purchase | Class A Common Stock | 139,595 | $20.8683 | $2.91M |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $20.43 to $21.05, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. These shares are held by Longitude Venture Partners IV, L.P ("LVPIV"). Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting and dispositive power over the shares held by LVPIV. The Reporting Person and Ms. Tammenoms Bakker are managing members of LCPIV and may be deemed to share voting and dispositive power with respect to the shares held by LVPIV. Each of LCPIV, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $21.67 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.
